Skip to main content
Fig. 1 | EJNMMI Research

Fig. 1

From: 18F-Fluciclovine PET metabolic imaging reveals prostate cancer tumour heterogeneity associated with disease resistance to androgen deprivation therapy

Fig. 1

a Schematic illustration of in vivo prostate orthograft models (CWR22Res and 22Rv1) to mimic clinical androgen-dependent and castration-resistant prostate cancer, respectively. There was a 21-day interval between the first and second PET/MRI scans (scan 1 and scan 2) on mice bearing CWR22Res (top panel) and 22Rv1 (bottom panel) orthografts, thus recapitulating tumour responses to clinical acute and chronic ADT. b Comparison of tumour volumes based on data from MRI scans (i) CWR22Res Scan 1 (pre-ADT) versus CWR22Res Scan 2 (post-ADT) (n = 4) (paired t test, p = 0.01) and (ii) 22Rv1 under chronic ADT scan 1 versus scan 2 (n = 3) (paired t test, p = 0.06). c Representative images of histological analysis of orthografts at the conclusion of experiment. Androgen-dependent (hormone naïve) CWR22Res tumours were from additional control mice that were not castrated. Within the design of the experiment, there were no matched tumours for 22Rv1 at the time of the first scan (scale bar = 100 µm)

Back to article page